Corpus Intelligence IC Memo — SUMMIT SURGICAL LLC 2026-04-27 01:02 UTC
IC Memo — SUMMIT SURGICAL LLC
Investment Committee Memorandum | KS | 10 beds | Grade C | EBITDA uplift $966K
🛡️ Public data only — no PHI permitted on this instance.
INVESTMENT COMMITTEE MEMORANDUM  ·  CCN 170198

SUMMIT SURGICAL LLC

LOCATIONRENO, KS·BEDS10·AS OFApril 27, 2026
C
INVESTABILITY
EBITDA BridgeData Room

1. Target Overview & Investment Thesis

SUMMIT SURGICAL LLC is a 10-bed suburban community hospital in RENO, KS with $13.1M in net patient revenue and a 5.2% operating margin. The hospital serves a payer mix of 39.8% Medicare, 0.4% Medicaid, and 59.8% commercial.

Thesis: Turnaround. Our ML models identify $966K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 5.2% to 12.6% (+738bps).

Net Revenue HCRIS$13.1M
Current EBITDA COMPUTED$686K
Operating Margin COMPUTED5.2%
Occupancy HCRIS24.4%
Revenue / Bed COMPUTED$1.3M
Net-to-Gross HCRIS37.2%
Distress Probability ML54.0%

2. Market Context & Competitive Position

152
KS Hospitals
-17.7%
State Median Margin
41
Comparable Hospitals

KS has 152 Medicare-certified hospitals with a median operating margin of -17.7%. The target's margin of 5.2% places it above the state median. Among 41 size-comparable peers (5-20 beds), the median margin is -22.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (5-20), prioritizing same-state peers. 41 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SUMMIT SURGICAL LLC (Target)KS10$13.1M5.2%
KANSAS CITY ORTHOPAEDIC INSTITKS17$86.3M21.1%
MANHATTAN SURGICAL HOSPITALKS13$42.0M13.1%
CLARA BARTON HOSPITAL ASSOCIATKS18$35.1M-8.2%
SUSAN B. ALLEN MEMORIAL HOSPITKS20$32.6M-18.5%
CLAY COUNTY MEDICAL CENTERKS20$30.5M-14.5%
SALINA SURGICAL HOSPITALKS16$28.3M20.9%
MIAMI COUNTY MEDICAL CENTERKS18$28.0M-17.2%
ANDERSON COUNTY HOSPITALKS12$27.8M-15.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $966K (738bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$275K+210bp18mo
Cost to Collect4.5%2.5%$262K+200bp12mo
Denial Rate Reduction12.0%6.5%$260K+199bp12mo
A/R Days Reduction5200.0%3800.0%$159K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+7bp6mo

5. EBITDA Bridge

Net Collection Rate
$275K
Cost to Collect
$262K
Denial Rate Reduction
$260K
A/R Days Reduction
$159K
Clean Claim Rate
$10K
Total EBITDA Uplift$966K
Current EBITDA$686K
+ RCM Uplift+$966K
Pro Forma EBITDA$1.7M
Current Margin5.2%
Pro Forma Margin12.6%
WC Released (1x)$502K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$1.1M$14.2M13.44x68.1%
Base (11x exit)10.0x11.0x$1.1M$15.9M15.11x72.1%
Bull Case9.0x11.0x$950K$19.5M20.50x83.0%
Bull (12x exit)9.0x12.0x$950K$21.5M22.66x86.7%
Bear Case11.0x10.0x$1.2M$9.0M7.76x50.7%
Bear (11x exit)11.0x11.0x$1.2M$10.3M8.86x54.7%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 24.4%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 54.0% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 41 hospitals with 5-20 beds
  • Same-state prioritization (n=45)
  • Comp margins: P25=-38.1% / P50=-22.0% / P75=-11.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 27, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.